


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

PATENT
Attorney Docket No.: 195531-001810US

2857
#6
5.13.02



On April 15, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Debra Ann DeBello
Debra Ann DeBello

RECEIVED
MAY - 3 2002
TC 2800 MAIL ROOM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hugh Young Rienhoff, Jr. *et al.*

Application No.: 09/808,442

Filed: March 13, 2001

For: AGGREGATING PERSONS WITH
A SELECT PROFILE FOR FURTHER
MEDICAL CHARACTERIZATION

Examiner: Unassigned

Art Unit: 2857

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
CFR §1.97 and §1.98

RECEIVED
APR 22 2002
TECHNOLOGY CENTER 2800

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Joseph R. Snyder
Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 925 472-5000
Fax: 925-472-8895
JS:ldr

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/808,442
Filing Date	March 13, 2001
First Named Inventor	Rienhoff, Hugh Young, Jr. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	19553I-001810US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	4,582,788		Henry A. Erlich	4/15/86	
	AB	5,075,217		James L. Weber	12/24/91	
	AC	5,840,746		Yves Ducharme et al.	11/24/98	
	AD	5,935,781		Poirier	08/1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AE		WO 97/40462	PCT		10/30/97		
	AF		WO 98/38846	PCT		9/11/98		
	AG		WO 98/07426	PCT		2/26/98		

RECEIVED
APR 22 2002
TECHNOLOGY CENTER 2800

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

WC 9040187 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **3**

Complete if Known

Application Number	09/808,442
Filing Date	March 13, 2001
First Named Inventor	Rienhoff, Hugh Young, Jr. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	195531-001810US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AH	Cheung, Kei-Hoi; Nadkarni, Prakash; Silverstein, Scot; Kidd, Judith R.; Pakstis, Andrew J.; Miller, Perry; and Kidd, Kenneth K.; <i>PhenoDB: An Integrated Client/Server Database for Linkage and Population Genetics</i> , <u>Computers and Biomedical Research</u> , August, 1996, Vol. 29, No. 4, pp. 327-337.	
	AI	Galfalvy, Hanga C. and Harner, James E., <i>A Statistical Environment for Multivariate Analyses</i> , <u>Proceedings of the 27th Symposium on the Interface Computing Science and Statistics</u> , June 21-24, 1995, Vol. 27, pp. 259-263.	
	AJ	Gould, K. Lance, <i>Invasive Procedures In Acute Myocardial Infarction: are they beneficial?</i> , <u>JAMA</u> , The Journal of the American Medical Association, September 21, 1994, Vol. 272, N. 11, p. 891(3).	
	AK	Hammond, Janet M. J.; Potgieter, Peter D.; Saunders, G. Lance and Forder, Arderne A.; <i>Double-bind study of selective decontamination of the digestive tract in intensive care</i> , <u>Lancet</u> , July 4, 1992, Vol. 340, No. 8810, p. 5(5).	
	AL	Munakata, Toshinori, <i>Knowledge-based systems for genetics</i> , <u>International Journal of Man-Machine Studies</u> , May 15, 1985, Vol. 23, No. 4, pp. 551-561.	
	AM	Ritter, O.; Kocab, P.; Senger, M.; Wolf, D.; and Suhai, S.; <i>Prototype Implementation of the Integrated Genomic Database</i> , <u>Computers and Biomedical Research</u> , April, 1992, Vol. 27, pp. 97-115.	
	AN	Schulz, Kenneth F.; Chalmers, Iain; Grimes, David A. and Altman, Douglas G.; <i>Assessing the Quality of Randomization from Reports of Controlled Trials Published in Obstetrics and Gynecology Journals</i> , <u>JAMA</u> , The Journal of the American Medical Association, July 13, 1994, V. 272, N. 2, p. 125(4).	
	AO	Srivastava et al., "Pharmacogenomics of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and the Cystic Fibrosis Drug CPX Using Genome Microarray Analysis", <u>Molecular Medicine</u> , Vol. 5, pp. 753-767 (1999).	
	AP	Ferrari, "Pharmacogenomics: a new approach to individual therapy of hypertension?", <u>Rapid Science Ltd.</u> , pp. 217-222 (1998).	
	AQ	Garry et al., "Estrogen Replacement Therapy. Serum Lipids, and Polymorphism of the Apolipoprotein E Gene", <u>Clinical Chemistry</u> , Vol. 45, no 8, pp. 1214-1223 (1999).	
	AR	Kroemer et al., "Molecular Bases and Clinical Consequences of Genetic Cytochrome P450 2D6 Polymorphism", <u>Life Sciences</u> , Vol. 56, no. 26, pp. 2285-2298 (1995).	

Examiner
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9040187 v1

Please type a plus sign (+) inside this box → ☐

APR 19 2002

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **3** of **3**

Complete if Known

Application Number	09/808,442
Filing Date	March 13, 2001
First Named Inventor	Rienhoff, Hugh Young, Jr. et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	195531-001810US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AS	Syvanne et al., "A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibric-Acid Derivative in Men after Coronary Bypass Surgery", Controlled Clinical Trials, Vol. 18, pp. 93-119 (1997).	
	AT	Lichter et al., "What's in a gene: using genetic information for the design of clinical trials", Current Opinion in Biotechnology, Vol. 6, pp. 715-717 (1995).	
	AU	Sanders, "Mining the Swedish Clinical Archives to Develop Pharmacogenomic Tests", Molecular Diagnosis, Vol. 4, No. 4, pp. 319-325 (December 1999).	
	AV	Nebert, "Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?", Clin Genet, Vol. 56, pp. 247-258 (October 1999).	
	AW	Stone et al., "PCR-RFLP typing of ureC from Helicobacter pylori isolated from gastric biopsies during a European multi-country clinical trial", The Journal of Antimicrobial chemotherapy, Vol. 40, pp. 251-256 (1997).	

RECEIVED

APR 22 2002

TECHNOLOGY CENTER 2800

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
WC 9040187 v1